Gaugh David Russell 4

What Happened

David Russell Gaugh, a director of Amphastar Pharmaceuticals, received equity awards reported on June 1, 2026. The Form 4 shows two grant entries: 8,143 shares (acquired, $0.00) and 17,365 derivative shares (acquired, $0.00), for a combined total of 25,508 RSU-type units. These were awards/grants (not open-market purchases) and carried no cash purchase price at grant.

Key Details

• Transaction date: June 1, 2026; Form 4 filed June 3, 2026 (appears timely).
• Grant amounts/prices: 8,143 shares @ $0.00 and 17,365 derivative shares @ $0.00 (total 25,508).
• Shares owned after transaction: not disclosed in this filing.
• Footnotes: F1 — reported shares are restricted stock units (RSUs) that vest on June 1, 2027. F2 — notes that option shares (if any) vest on June 1, 2027; no option exercise is reported here.
• Transaction code: A (award/grant).

Context

These awards are compensation (RSUs) that convert to actual shares if and when they vest (here, one year from grant). This is a standard equity grant rather than an insider buying stock on the open market, so it should be viewed as part of pay/retention, not a direct buy signal.